Name: | tenecteplase |
---|---|
Name (isomeric): | DB00031 |
Drug Type: | biotech |
Synonyms: |
tPA; t-plasminogen activator; Tissue-type plasminogen activator precursor; t- PA
|
Brand: | TNKase (Genentech Inc) |
Category: | Thrombolytic Agents |
CAS number: | 191588-94-0 |
Indication: | For treatment of myocardial infarction and lysis of intracoronary emboli |
---|---|
Pharmacology: | Tenecteplase is a fibrin-specific tissue-plasminogen activator. It binds to fibrin rich clots and cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. This helps eliminate blood clots or arterial blockages that cause myocardial infarction. |
Mechanism of Action: | Tenecteplase binds to fibrin rich clots via the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, thereby exerting its thrombolytic action. |
Half Life: | 1.9 hours (mammalian reticulocytes, in vitro) >20 hours (yeast, in vivo) >10 hours (Escherichia coli, in vivo) |
Clearance: | 99 - 119 mL/min [acute myocardial infarction patients] |
Affected organisms: | Humans and other mammals |
Drug interaction: |
|
---|